Rabbit Recombinant Monoclonal FOXC2 antibody. Suitable for ICC, IP, WB and reacts with Human, Mouse samples. Immunogen corresponding to Synthetic Peptide within Human FOXC2 aa 350-400.
pH: 7.8 - 8.6
Preservative: 0.09% Sodium azide
Constituents: 98% Borate buffered saline
ICC | IP | WB | |
---|---|---|---|
Human | Tested | Tested | Tested |
Mouse | Tested | Expected | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse | Dilution info - | Notes - |
FKHL14, MFH1, FOXC2, Forkhead box protein C2, Forkhead-related protein FKHL14, Mesenchyme fork head protein 1, Transcription factor FKH-14, MFH-1 protein
Rabbit Recombinant Monoclonal FOXC2 antibody. Suitable for ICC, IP, WB and reacts with Human, Mouse samples. Immunogen corresponding to Synthetic Peptide within Human FOXC2 aa 350-400.
pH: 7.8 - 8.6
Preservative: 0.09% Sodium azide
Constituents: 98% Borate buffered saline
FOXC2 also known as Forkhead Box C2 is a transcription factor weighing approximately 55 kDa. It is a part of the FOX family of transcription factors characterized by a distinct forkhead DNA-binding domain. FOXC2 expresses in various tissues including adipose tissue blood vessels and mesenchymal cells. Its role is to regulate the expression of genes involved in development and differentiation.
This transcription factor plays a significant role in the development of the cardiovascular and lymphatic systems. It functions as part of a complex network working with other transcription factors to control gene expression that governs vascular remodeling and lymphangiogenesis. Through its activity FOXC2 influences cell fate decisions impacting tissue formation and function during embryogenesis and adult life.
FOXC2 participates notably in the TGF-beta signaling pathway. It interacts with SMAD family proteins to influence cellular responses to transforming growth factor-beta signals which are important for cellular proliferation and differentiation. FOXC2 also interfaces with other signaling pathways working in tandem with proteins like Notch and VEGF to modulate angiogenesis and vascular homeostasis.
FOXC2 mutations and dysregulation associate with lymphedema-distichiasis syndrome and various types of cancer. It frequently interacts with other proteins such as VEGFR-3 in these conditions. Mutations affecting FOXC2 can lead to abnormal lymphatic development contributing to fluid retention and limb swelling in lymphedema. In cancer FOXC2 acts as a regulator of cell invasion and metastasis indicating its potential as a therapeutic target.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Samples: Whole cell lysate (50 µg) from NIH 3T3, CT26, and CH27 cells prepared using NETN lysis buffer. Antibody:Rabbit anti-FOXC2 recombinant monoclonal antibody [BLR184J] (A700-184 lot 1) used at 1:1000. Secondary:HRPconjugated goat anti-rabbit IgG (A120-101P). Chemiluminescence with an exposure time of 3 minutes. Lower Panel: Rabbit anti-COPB2 antibody (A304-523A).
All lanes: Western blot - Anti-FOXC2 antibody [BLR184J] - BSA free (ab314051) at 1/1000 dilution
Lane 1: NIH 3T3 Whole cell lysate at 50 µg
Lane 2: CT 26 Whole cell lysate at 50 µg
Lane 3: CH 27 Whole cell lysate at 50 µg
All lanes: HRP conjugated goat anti-rabbit IgG
Samples: Whole cell lysate (50 µg) from HeLa, HeLa NE (25 µg), OVCAR-3, MCF-7, and GaMG cells prepared using NETN lysis buffer. Antibody: Rabbit anti-FOXC2 recombinant monoclonal antibody [BLR184J] used at 1:1000. Secondary: HRP-conjugated goat anti-rabbit IgG. Chemiluminescence with an exposure time of 75 seconds. Lower Panel: Rabbit anti-Actin recombinant monoclonal antibody [BLR057F]
All lanes: Western blot - Anti-FOXC2 antibody [BLR184J] - BSA free (ab314051) at 1/1000 dilution
Lane 1: HeLa Whole cell lysate at 50 µg
Lane 2: HeLa NE Whole cell lysate at 50 µg
Lane 3: OVCAR-3 Whole cell lysate at 50 µg
Lane 4: MCF-7Whole cell lysate at 50 µg
Lane 5: GaMG Whole cell lysate at 50 µg
All lanes: HRP-conjugated goat anti-rabbit IgG
Samples: HeLa nuclear extract (1.0 mg per IP reaction; 5% of IP loaded). Antibodies: Rabbit anti-FOXC2 recombinant monoclonal antibody [BLR184J] used for IP at 20 µl/mg lysate. FOXC2 was also immunoprecipitated by a second antibody against a different epitope of FOXC2 (BL-1796A-1A7). For blotting immunoprecipitated FOXC2, A700-184 was used at 1:1000. Chemiluminescence with an exposure time of 30 seconds.
Detection of human FOXC2 in HeLa cells by ICC. Antibody: Rabbit anti-FOXC2 recombinant monoclonal antibody [BLR184J]. Secondary: HRP-conjugated goat anti-rabbit IgG. Substrate: DAB
Detection of human FOXC2 in Ovcar-3 cells by ICC . Antibody: Rabbit anti-FOXC2 recombinant monoclonal antibody [BLR184J] (A700-184 lot 1). Secondary: HRPconjugated goat anti-rabbit IgG . Substrate: DAB
Detection of mouse FOXC2 in 3T3 cells by ICC.Antibody: Rabbit anti-FOXC2 recombinant monoclonal antibody [BLR184J]. Secondary: HRP-conjugated goat anti-rabbit IgG Substrate: DAB
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com